{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:12:37Z","timestamp":1760213557561,"version":"build-2065373602"},"reference-count":6,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvoice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Voice"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jvoice.2020.11.028","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T18:59:08Z","timestamp":1610132348000},"page":"257-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Reversible Bevacizumab Induced Vocal Fold Necrosis"],"prefix":"10.1016","volume":"37","author":[{"given":"Anita","family":"Sulibhavi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senthuran","family":"Tharmalingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liane","family":"McCarroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed M.S.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvoice.2020.11.028_bib0001","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000236988","article-title":"Vascular permeability factor\/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation","volume":"107","author":"Dvorak","year":"1995","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jvoice.2020.11.028_bib0002","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1634\/theoncologist.2009-0317","article-title":"Bevacizumab","volume":"15","author":"Kazazi-Hyseni","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.jvoice.2020.11.028_bib0003","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamaoto.2014.1766","article-title":"Hoarseness after metastatic colon cancer treatment","volume":"140","author":"Caruso","year":"2014","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jvoice.2020.11.028_bib0004","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/annonc\/mdr515","article-title":"Bevacizumab-induced laryngeal necrosis","volume":"23","author":"Hartl","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jvoice.2020.11.028_bib0005","doi-asserted-by":"crossref","first-page":"H547","DOI":"10.1152\/ajpheart.00616.2005","article-title":"Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling","volume":"290","author":"Baffert","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jvoice.2020.11.028_bib0006","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1177\/1078155219889388","article-title":"Bevacizumab-induced dysphonia: a case report with a brief review of literature","volume":"26","author":"Lam","year":"2020","journal-title":"J Oncol Pharm Pract"}],"container-title":["Journal of Voice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0892199720304318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0892199720304318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:42:28Z","timestamp":1760211748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0892199720304318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":6,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0892199720304318"],"URL":"https:\/\/doi.org\/10.1016\/j.jvoice.2020.11.028","relation":{},"ISSN":["0892-1997"],"issn-type":[{"type":"print","value":"0892-1997"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversible Bevacizumab Induced Vocal Fold Necrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Voice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvoice.2020.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Voice Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}